🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

On March 31, 1941, Dr Saul Hertz rushed over the Harvard Bridge at Massachusetts Institute of Technology with a flask of cyclotron-produced radioiodine, and for the first time administered it therapeutically to a patient. This pioneering treatment for thyroid cancer laid the

A first patient has been dosed in Telix’s Phase 1 ZOLAR trial which aims to validate the use of olaratumab, an antibody exclusively licensed from Lilly, as a potential treatment for advanced, metastatic soft tissue sarcoma (STS), after radiolabelling. Although localized STS

Telix today announces the appointment of Anne Whitaker as a Non-Executive Director. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years’ global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including

Telix has appointed Dr. Paul Schaffer to the newly-created role of Chief Technology Officer (CTO). Dr. Schaffer has been CTO at ARTMS for the past seven years and is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program. This

Telix has issued a statement in response to international trade tariffs recently levied by the U.S. government. The Company advises that it does not expect any material impact on its business or supply chain. Read the full statement on our website here: bit.ly/42aKJ4o

Telix today announces that its prostate cancer imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been approved by the Irish Health Products Regulatory Authority (HPRA). Illuccix’s broad indication in Ireland will help ensure extensive

Telix today announces Cardinal Health as a commercial distributor for Gozellix®. Following recent FDA approval, and in preparation for commercial launch this quarter, Telix has contracted with Cardinal Health to enable availability across a wide range of U.S. locations. To

Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is now approved in Sweden, supporting broader access to gallium-based PSMA-PET imaging for Swedish patients. Prostate cancer is the most common cancer among men in Sweden and Illuccix’s broad indication will

Telix has announced positive preliminary results from the Phase 2 IPAX-Linz investigator-initiated trial of TLX101 (131I-iodofalan) therapy in recurrent high-grade glioma (brain cancer). TLX101 potentially offers a novel mode of action for treating gliomas by utilizing a small

Telix provides notice of the Annual General Meeting of shareholders: 🌏The Wesley Conference Centre, Lyceum Room, 220 Pitt Street, Sydney, NSW and online 🕙 Wednesday 21 May 2025 at 10.00am (AEST) For full details of the meeting including an explanatory memorandum,

Telix today provides a performance update for Q1 2025, reporting unaudited revenue of US $186 million – a 62% increase year-on-year. This strong result was primarily driven by the ongoing momentum of Illuccix®, Telix’s PSMA-PET imaging agent, which continues to gain market share

Join Telix this weekend at the American Urological Association's 2025 Annual Meeting - the largest gathering of urologists worldwide. #AUA2025 will feature four abstract presentations on Telix’s late-stage and commercial theranostic programs, including ProstACT Global,

Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is now approved in France, supporting broader access to gallium-based PSMA-PET imaging for French patients. Prostate cancer remains the most common cancer among French men, with over 57,000 new cases

Hei Suomi! 🇫🇮 Great news for Finland! Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is now approved, marking a significant milestone for thousands of Finnish men with prostate cancer. Following recent approvals in Sweden, Norway, and Denmark,

This May, Telix is proudly "going gray" to support Brain Tumor Awareness Month. Despite ongoing research, treatment options for many primary brain tumors remain limited with poor patient outcomes. This month aims to raise awareness about the challenges faced by these patients

Ahoj Česká republika! Great news for Czechs! Illuccix® (kit for the preparation of gallium-68 gozetotide injection) is now approved, marking a significant milestone for thousands of men with prostate cancer in the Czech Republic. With its broad indication and ready-to-use

Telix is pleased to once again support the European Association of Nuclear Medicine (EANM) Sanjiv Sam Gambhir Young Investigator Award. This is an incredible opportunity for a junior physician or scientist up to the age of 38 to further develop their career in

Telix’s Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. Dr. Sanjana Ballal and colleagues conclude that TLX400 demonstrates encouraging safety profile and efficacy

Gliomas are the most common type of malignant brain tumor, accounting for around 80% of all cases. The most aggressive form, glioblastoma, has a median survival of just 12 to 15 months after diagnosis. Diagnosing and treating these gliomas is complex and current